文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > 调强放疗局部晚期食管癌
侵权投诉

调强放疗局部晚期食管癌

调强放疗联合卡培他滨治疗局部晚期食管癌的临床观察

陈敬生 ,孟平,许浩,李宝,金军 (鄂州市中心医院肿瘤科,湖北 鄂州,436000)

摘要:目的 观察调强放疗联合卡培他滨治疗局部晚期食管癌的临床疗效。方法 74例局部晚期食管癌患者

随机分两组:放疗同步卡培他滨组23例(观察组),单纯放疗组22例(对照组)。二组均采用调强放疗(分割照射,1次/天,2Gy/次,5次/周,总剂量60-66Gy/30-33次/6-7周)。观察组在放疗期间口服卡培他滨1000mg/m2,2次/天,连用14天后停药7天,21天为一个疗程,共治疗2个疗程。结果 45例患者均按计划完成治疗,放疗结束后第8周复查,对照组和试验组的治疗总有效率分别为63.6%和82.6%,差异有统计学意义(p<0.05)。试验组手足综合征及腹泻的发生率显著高于对照组(p<0.05),均为Ⅰ-Ⅱ级,两组其它不良反应如骨髓抑制、恶心、呕吐、放射性食管炎及放射性肺炎的发生率比较均无统计学差异(p>0.05)。结论 相对于单纯放疗,卡培他滨联合三维适形放疗技术可提高老年中晚期食管癌的近期疗效,患者的不良反应有所增加,但患者均可耐受,值得临床进一步探讨。

关键词:老年食管癌;三维适形放疗;化疗;卡培他滨;临床疗效

Observation on the Clinical Efficacy of Capecitabine plus Three Dimensional Conformal Radiation Therapy For Elderly Patients with Middle-Advanced Stage Esophageal Carcinoma

Cheng Jingsheng ,Meng Ping ,Qiao Xiaoyan, Hu Guocheng, Jin Jun (Department of Oncology of Ezhou Central Hospital, Ezhou, Hubei, 436000)

Abstract: Objective To observe the short-term clinical efficacy and adverse reaction of Capecitabine plus

three-dimensional conformal radiotherapy in the elderly patients with Middle-advanced stage esophageal carcinoma. MethodsForm December 2010 to October 2012, 45 elderly patients with Middle-advanced stage esophageal carcinoma were randomized into three-dimensionalconformal radiotherapy (control group) and Capecitabine plus three-dimensional conformal radiotherapy (experimental group): the control group had 22 patients and experimental group had 23 patients. Radiotherapy in both groups was similar.All patients in the two groups was treated with three-dimensional conformal radiotherapy (1 time per day, 2 Gy per fraction, 5 fraction per week with the total dose of 60-66Gy/30-33f /6-7w). The expermental group was received capecitabine (1 000 mg/m2, 2 times per day, from the 1st

作者简介:陈敬生(1977-10),医师,研究方向:肿瘤综合治疗,E-mail:cjs1025@163.com。

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email